机构：[1]Department of General Practice, The First Affiliated Hospital of Kunming Medical University, Kunming, China.昆明医科大学附属第一医院干疗科内科科室[2]The Second Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, China.昆明医科大学附属第一医院呼吸与危重症二科呼吸内科内科科室[3]Institute of School Health, Yunnan Center for Disease Control and Prevention, Kunming, China.[4]School of Basic Medical Sciences, Kunming Medical University, Kunming, China.
The immune-related adverse events associated with immunotherapy may affect endocrine glands and other tissues. Two Chinese patients with malignancies were treated with programmed cell death-1 (PD-1) inhibitors (nivolumab and pembrolizumab) and followed up with biochemical tests over 1 year. After PD-1 treatment for 6 to 10 months, the patients developed symptoms of diabetes, ketoacidosis, and insulin secretion failure. Type 1 diabetes mellitus was confirmed by the characteristic fluctuation of blood glucose that was controlled with multiple daily insulin injections. Neither patient's insulin depletion status was reversed in subsequent years. To decrease the life-threatening complications of diabetic hyperosmolar syndrome and ketoacidosis caused by type 1 diabetes mellitus, it is necessary to monitor the blood glucose and hemoglobin A1c levels. Islet β-cell autoantibodies and human leukocyte antigen genes can provide additional information in select cases.
基金：
This work
was supported by grants from the National
Natural Science Foundation of China
(81960156), High Level Health Technology
Personnel Training Project of Yunnan Province
(D-2018044), Health Science and Technology
Program of Yunnan Province [2019FE001
(-040)], and the Joint Project of Kunming
Medical University and Science and
Technology Agency (202101AY070001-049).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2023]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
JCR分区：
出版当年[2022]版：
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
最新[2023]版：
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
第一作者机构：[1]Department of General Practice, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of General Practice, The First Affiliated Hospital of Kunming Medical University, Kunming, China.[*1]Department of General Practice, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Wuhua District, Kunming 650032, China
推荐引用方式(GB/T 7714)：
Luo Jingmei,Feng Jiagang,Liu Chunyan,et al.Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases[J].JOURNAL OF INTERNATIONAL MEDICAL RESEARCH.2022,50(9):doi:10.1177/03000605221121940.
APA：
Luo Jingmei,Feng Jiagang,Liu Chunyan,Yang Zhongce,Zhan Dong...&Zhang Lihua.(2022).Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.JOURNAL OF INTERNATIONAL MEDICAL RESEARCH,50,(9)
MLA：
Luo Jingmei,et al."Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases".JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 50..9(2022)
